Clinical Trial Update: Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly [Phase 1]

View source ↗

Summary

This Phase 1 safety pharmacokinetics study evaluated the effects of mild and moderate renal impairment on the pharmacokinetics of ABT-335 when given with rosuva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Renal Insufficiency

Drugs mentioned

• ABT-335
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Dyslipidemia, Renal Insufficiency | Phase 1 | Status: COMPLETED